Working... Menu
Trial record 1 of 1 for:    NCT00584493
Previous Study | Return to List | Next Study

Treatment Use Study for Advanced Melanoma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00584493
Expanded Access Status : No longer available
First Posted : January 2, 2008
Last Update Posted : December 14, 2009
Information provided by:

Tracking Information
First Submitted Date December 21, 2007
First Posted Date January 2, 2008
Last Update Posted Date December 14, 2009
Descriptive Information
Brief Title Treatment Use Study for Advanced Melanoma.
Brief Summary The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.
Detailed Description This is an expanded access trial that canceled prior to enrolling patients.
Study Type Expanded Access
Intervention Drug: CP-675,206

This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma

Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206.

Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status No longer available
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT00584493
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor Pfizer
Collaborators Not Provided
Study Director: Pfizer Call Center Pfizer
PRS Account Pfizer
Verification Date December 2009